Brief: PCI Biotech Holding successful completion of the third dose cohort
Aug 18 (Reuters) - PCI Biotech Holding ASA PCIB.OL :
* Successful completion of the third dose cohort in the
study for patients with inoperable bile duct cancer
* No safety concerns were observed at this dose level
Source text for Eikon: ID:nHUG4ZHygd
Further company coverage: PCIB.OL
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48586983920;))
Recent news on PCI Biotech Holding ASA
See all newsBrief: Euronext Oslo Børs To Delist PCI Biotech Holding Shares
Brief: Euronext Oslo Børs Gets Application From PCI Biotech Holding For Delisting
Brief: PCI Biotech Holding Board Proposes Dissolution, Delisting
Brief: Oslo Bors: PCI Biotech Holding Is Placed In Recovery Box
Brief: PCI Biotech Says Co Initiates Process To Evaluate Opportunity For Structured Wind-Up Process